MET and breast carcinoma: For example, the NCT03060356 trial of c-Met-specific CAR-Ts for advanced melanoma or breast cancer [191] was terminated in 2020 with no results published, despite the previous inspiring results on the safety and efficacy of intratumoral delivery of c-Met-CAR-Ts [192].